There was a time, back in biotech’s leaner years, when any company hoping to raise even a dollar needed a clear path to get a single drug through clinical trials.
Now, in today’s gilded age of VC largesse, companies can raise nine-figure funding rounds without so much as deciding on a discrete disease area.
About the Author Reprints
